GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Zeo ScientifiX Inc (OTCPK:ZEOX) » Definitions » Asset Turnover

Zeo ScientifiX (Zeo ScientifiX) Asset Turnover : 0.95 (As of Jan. 2024)


View and export this data going back to 2013. Start your Free Trial

What is Zeo ScientifiX Asset Turnover?

Asset Turnover measures how quickly a company turns over its asset through sales. It is calculated as Revenue divided by Total Assets. Zeo ScientifiX's Revenue for the three months ended in Jan. 2024 was $1,154 Mil. Zeo ScientifiX's Total Assets for the quarter that ended in Jan. 2024 was $1,217 Mil. Therefore, Zeo ScientifiX's Asset Turnover for the quarter that ended in Jan. 2024 was 0.95.

Asset Turnover is linked to ROE % through Du Pont Formula. Zeo ScientifiX's annualized ROE % for the quarter that ended in Jan. 2024 was 551.27%. It is also linked to ROA % through Du Pont Formula. Zeo ScientifiX's annualized ROA % for the quarter that ended in Jan. 2024 was -341.71%.


Zeo ScientifiX Asset Turnover Historical Data

The historical data trend for Zeo ScientifiX's Asset Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zeo ScientifiX Asset Turnover Chart

Zeo ScientifiX Annual Data
Trend Oct14 Oct15 Oct16 Oct17 Oct18 Oct19 Oct20 Oct21 Oct22 Oct23
Asset Turnover
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4.44 3.08 3.43 1.60 1.02

Zeo ScientifiX Quarterly Data
Apr19 Jul19 Oct19 Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24
Asset Turnover Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 203.44 0.22 0.42 0.54 0.95

Competitive Comparison of Zeo ScientifiX's Asset Turnover

For the Biotechnology subindustry, Zeo ScientifiX's Asset Turnover, along with its competitors' market caps and Asset Turnover data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Zeo ScientifiX's Asset Turnover Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Zeo ScientifiX's Asset Turnover distribution charts can be found below:

* The bar in red indicates where Zeo ScientifiX's Asset Turnover falls into.



Zeo ScientifiX Asset Turnover Calculation

Asset Turnover measures how quickly a company turns over its asset through sales.

Zeo ScientifiX's Asset Turnover for the fiscal year that ended in Oct. 2023 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (A: Oct. 2023 )/( (Total Assets (A: Oct. 2022 )+Total Assets (A: Oct. 2023 ))/ count )
=4.558/( (6.201+2.782)/ 2 )
=4.558/4.4915
=1.01

Zeo ScientifiX's Asset Turnover for the quarter that ended in Jan. 2024 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (Q: Jan. 2024 )/( (Total Assets (Q: Oct. 2023 )+Total Assets (Q: Jan. 2024 ))/ count )
=1154/( (2.782+2432)/ 2 )
=1154/1217.391
=0.95

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Companies with low profit margins tend to have high Asset Turnover, while those with high profit margins have low Asset Turnover. Companies in the retail industry tend to have a very high turnover ratio.


Zeo ScientifiX  (OTCPK:ZEOX) Asset Turnover Explanation

Asset Turnover is linked to ROE % through Du Pont Formula.

Zeo ScientifiX's annulized ROE % for the quarter that ended in Jan. 2024 is

ROE %**(Q: Jan. 2024 )
=Net Income/Total Stockholders Equity
=-4160/-754.6205
=(Net Income / Revenue)*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-4160 / 4616)*(4616 / 1217.391)*(1217.391/ -754.6205)
=Net Margin %*Asset Turnover*Equity Multiplier
=-90.12 %*3.7917*-1.6132
=ROA %*Equity Multiplier
=-341.71 %*-1.6132
=551.27 %

Note: The Net Income data used here is four times the quarterly (Jan. 2024) net income data. The Revenue data used here is four times the quarterly (Jan. 2024) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** The ROE % used above is for Du Pont Analysis only. It is different from the defined ROE % page on our website, as here it uses Net Income instead of Net Income attributable to Common Stockholders in the calculation.

It is also linked to ROA % through Du Pont Formula:

Zeo ScientifiX's annulized ROA % for the quarter that ended in Jan. 2024 is

ROA %(Q: Jan. 2024 )
=Net Income/Total Assets
=-4160/1217.391
=(Net Income / Revenue)*(Revenue / Total Assets)
=(-4160 / 4616)*(4616 / 1217.391)
=Net Margin %*Asset Turnover
=-90.12 %*3.7917
=-341.71 %

Note: The Net Income data used here is four times the quarterly (Jan. 2024) net income data. The Revenue data used here is four times the quarterly (Jan. 2024) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Therefore, it is a good sign if a company's Asset Turnover is consistent or even increases. If a company's asset grows faster than sales, its Asset Turnover will decline, which can be a warning sign.


Zeo ScientifiX Asset Turnover Related Terms

Thank you for viewing the detailed overview of Zeo ScientifiX's Asset Turnover provided by GuruFocus.com. Please click on the following links to see related term pages.


Zeo ScientifiX (Zeo ScientifiX) Business Description

Traded in Other Exchanges
N/A
Address
3321 College Avenue, Suite 246, Davie, FL, USA, 33314
Organicell Regenerative Medicine Inc is a clinical-stage biopharmaceutical company principally focusing on the development of innovative biological therapeutics for the treatment of degenerative diseases and regenerative medicine. Its product candidate, Zofinis an acellular, biologic therapeutic derived from perinatal sources and is manufactured to retain naturally occurring microRNAs, without the addition or combination of any other substance or diluent. Zofin is in Phase I/II clinical trials to treat Long COVID and COPD and Osteoarthritis. The company has entered an agreement with CDC to determine the anti-inflammatory and anti-infective effectiveness of Zofin in experimental models of influenza infection.
Executives
Skycrest Holdings, Llc 10 percent owner 1930 HARRISON STREET, SUITE 204, HOLLYWOOD FL 33020
Harry L. Leider director, officer: CEO and Director C/O GELESIS, INC., 501 BOYLSTON STREET, SUITE 6102, BOSTON MA 02116
Howard Lawrence Golub officer: Executive Vice President & CSO 23648 SEPTEMBER SUN SQ, ASHBURN VA 20148
Matthew Phillip Sinnreich officer: COO and Acting CEO 4045 SHERIDAN AVENUE, SUITE 239, MIAMI BEACH FL 33139
Steven Jerry Glauser director 1428 BRICKELL AVENUE, SUITE 105, MIAMI FL 33131
Leathem S Stearn director 2306 BAY DRIVE, POMPANO BEACH FL 33062
Charles Luther Bretz director 58 N. CHICAGO ST, 2ND FLOOR, JOLIET IL 60432
Bhupendra Kumar Modi director 6 MARINA BOULEVARD, #63-18, THE SALE @ MARINA BAY U0 018985
Gurvinder Pal Singh director E - 128, FIRST FLOOR, GREATER KAILASH - II, NEW DELHI K7 110048
John F Chiste director
Ryan C Likes officer: Chief Operating Officer 1116 MEADOWBROOK AVE., LOS ANGELES CA 90019
Greyt Ventures, Llc 10 percent owner GREYT VENTURES, LLC, 20533 BISCAYNE BOULEVARD, SUITE 648, AVENTURA FL 33180
Wendy Grey 10 percent owner GREYT VENTURES, LLC, 20533 BISCAYNE BOULEVARD, SUITE 648, AVENTURA FL 33180
Ian T Bothwell 10 percent owner, officer: Chief Financial Officer 77 530 ENFIELD LANE, BLDG D, PALM DESERT CA 92211
Albert Mitrani director, officer: Chief Executive Officer 4045 SHERIDAN AVE., SUITE 239, MIAMI BEACH FL 33140